New York-based virtual women's health provider Maven Clinic has announced a strategic partnership with health-tracking ring manufacturer Oura, enabling integration of biometric data into Maven’s clinical care delivery. The collaboration allows Oura Ring users to synchronize their health data directly with Maven's digital platform, creating new opportunities for data-driven healthcare interventions.
Maven Clinic operates as a comprehensive digital reproductive health and family platform, delivering fertility and family planning services, pregnancy and postpartum care, parenting and pediatric support, and menopause-related healthcare solutions. Through this partnership, Maven's clinical care teams will gain access to continuous biometric insights from Oura Ring wearers, including detailed sleep patterns, stress indicators, and activity metrics.
The integration represents an advancement in personalized healthcare delivery, allowing clinicians to make more informed decisions based on real-time physiological data. Eligible Maven members will also benefit from exclusive pricing opportunities when purchasing Oura Ring devices, making the technology more accessible to the platform's user base.
"At Oura, we're focused on integrating our continuous biometric insights into clinical conversations—ensuring that real-time data actively informs and enhances the care people receive," said Dorothy Kilroy, chief commercial officer at Oura. "Our partnership with Maven Clinic brings that vision to life, helping providers deliver more timely, personalized support grounded in each individual's unique health patterns. It's the future of women's health—evidence-based, deeply personalized, and clinically actionable."
This partnership builds on Maven Clinic's recent expansion efforts, including collaborations with Manulife Canada and AT&T to extend digital health services to employees. The company has demonstrated a strong growth trajectory, securing $125 million in funding that elevated its valuation to $1.7 billion, following previous funding rounds totaling $200 million.
Similarly, Oura continues expanding its healthcare partnerships, recently enhancing its collaboration with Dexcom to integrate glucose monitoring capabilities and participating in opioid use disorder prevention research with multiple academic and healthcare institutions. The company appointed its first chief medical officer in March and completed a $200 million Series D funding round, achieving a $5.2 billion valuation.
Click here for the original news story.